Iron Park Capital Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Iron Park Capital Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-179,434	Closed	-$1.79M	–	46
2022 Q1	$1.79M	Buy	179,434 +117,218	+188%	+$1.17M	1.51%	25
2021 Q4	$615K	Buy	+62,216	New	+$618K	0.49%	36

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Iron Park Capital Partners's MLTX Position: Q2 2022 in Review

Iron Park Capital Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2022, closing a stake of 179,434 shares — an estimated $1.79M sold.

Iron Park Capital Partners first reported a position in MLTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.79M in Q1 2022. 23 funds tracked by Wall St. Rank hold MLTX as of Q2 2022.

Iron Park Capital Partners reported no remaining MoonLake Immunotherapeutics position as of Q2 2022 after selling out during the quarter.
Iron Park Capital Partners sold 179,434 MoonLake Immunotherapeutics shares in Q2 2022, an estimated $1.79M.
Iron Park Capital Partners first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 2 quarters.
Iron Park Capital Partners's MoonLake Immunotherapeutics position peaked at $1.79M in Q1 2022.
23 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2022.

Based on Iron Park Capital Partners's 13F filing for Q2 2022, filed 11 Aug 2022.